Faktenthread und Linksammlung zu AGIX

Stelle hier mal nen paar Links rein zu nützlichen Seiten um die Aktie von AGIX gut verfolgen zu können:

1: Yahoo-Diskussionsboard

http://messages.finance.yahoo.com/...o_Z%29/Stocks_A/forumview?bn=555

2: Realtime BIDs und ASKs

http://datasvr.tradearca.com/arcadataserver/...hp?Symbol=agix&x=0&y=0

3: Homepage von AtheroGenics

http://www.atherogenics.com/investor/stock.html

4: Realtimechart von AGIX inkl. Volumen

http://de.advfn.com/p.php?pid=staticchart&s=N%5EAGIX&p=0&t=16&vol=1

5: Investorshub

http://investorshub.advfn.com/boards/board.asp?board_id=3880

6: Hauptthread AGIX bei Ariva

http://www.ariva.de/Megarebound_koennte_folgen_wenn_t319076

7: Chartanalyse

http://stockcharts.com/h-sc/ui?s=AGIX&p=D&b=5&g=0&id=0



Die kommenden NEWS können und sollten hier auch reingestellt werden was natürlich jeder machen kann der Interesse dran hat.

Wenn jemand meint das hier ältere NEWS auch rein sollten kann er Sie gerne reinsetzen aber bitte nur wirklich relevante NEWS nicht jeden Schitt.

Habe diesen Zusatzthread eröffnet weil ich per BM drauf angesprochen wurde ob ich so was mal machen könnte und auch weil ich glaube das AGIX uns noch lange beschäftigen wird da ich an eine Zulassung von AGI-1067 glaube und dann gehts ja erst richig rund.

Also laßt uns diesen Thread nicht zum diskuttieren benutzen sondern für Fakten und Links die wichtig sind damit sich auch Neueinsteiger schnell zurechtfinden können.

In diesem Sinne viel Erfolg uns allen.

AtheroGenics is a publicly traded, emerging pharmaceutical company focused on the discovery, development and commercialization of novel pharmaceutical products that address critical unmet needs in the treatment of chronic inflammatory diseases, including diabetes and atherosclerosis.

The Company’s lead compound, AGI-1067, is a novel orally available anti-oxidant with anti-inflammatory properties that was discovered by AtheroGenics scientists.

AtheroGenics is studying AGI-1067 in a Phase III clinical trial called ANDES (AGI-1067 as a Novel Anti-Diabetic Agent Evaluation Study) to assess the ability of AGI-1067 to control blood sugar levels in patients with diabetes. Patient enrollment in ANDES was completed in December 2007. A pre-planned interim analysis to evaluate the efficacy and safety of AGI-1067 after three months of dosing will be conducted in the second quarter of 2008. The Company expects to release final data on the full six months of dosing during the second half of 2008.

AtheroGenics was incorporated in Georgia in 1993 and is based in Alpharetta, Georgia. The Company currently has 70 employees, with a senior management team comprised of executives from leading pharmaceutical companies and academic institutions.  

AtheroGenics Regains Compliance With NASDAQ Listing Requirement
Tuesday March 4, 7:15 am ET

ATLANTA, GA--(MARKET WIRE)--Mar 4, 2008 -- AtheroGenics, Inc. (NasdaqGM:AGIX - News), a pharmaceutical company focused on the treatment of chronic inflammatory diseases, today announced that the NASDAQ Listing Qualifications Panel has granted the Company's request for continued listing of its securities on The NASDAQ Global Market. The company filed its Form 10-K on March 3, 2008, evidencing that it satisfied a NASDAQ requirement to have more than $50 million in revenue and $50 million in total assets for the fiscal year ended December 31, 2007.

ADVERTISEMENT
As previously announced, the Company had received notice of non-compliance from NASDAQ due to the Company's failure to evidence that the market value of its common shares was above the $50 million requirement for continued listing on the NASDAQ Global Market, as required by Marketplace Rule 4450(b)(1)(A). In response, the company appeared before the NASDAQ Panel and presented its plan, which was subsequently accepted by the Panel, to evidence compliance with the alternative listing standard that requires $50 million in total assets and $50 million in total revenue in the most recent fiscal year. Upon the filing of the Form 10-K for the fiscal year ended December 31, 2007, AtheroGenics reported total assets of $103.1 million and total revenues of $52.3 million.

AtheroGenics to Present at Lehman Brothers Global Healthcare Conference March 18, 2008
ATLANTA, GA -- (MARKET WIRE) -- 03/11/2008 -- AtheroGenics, Inc. (NASDAQ: AGIX), a pharmaceutical company focused on the treatment of chronic inflammatory diseases, today announced that Russell M. Medford, M.D., Ph.D., President and Chief Executive Officer, will be presenting a company overview and update at the upcoming 11th Annual Lehman Brothers Global Healthcare Conference on Tuesday, March 18, 2008, at 3:45 p.m. Eastern Daylight Time at the Loews Miami Beach Hotel in South Beach, Florida.

A live audio webcast of the presentation will be available on the AtheroGenics Investor Relations Events website at www.atherogenics.com. A replay of the presentation will be available on the Company's website approximately twenty-four hours after the presentation and will be archived for thirty days.

About AtheroGenics

AtheroGenics is focused on the discovery, development and commercialization of novel drugs for the treatment of chronic inflammatory diseases, including diabetes and coronary heart disease (atherosclerosis). AtheroGenics has completed patient enrollment in ANDES (AGI-1067 as a Novel Anti-Diabetic Agent Evaluation Study), a Phase III clinical trial evaluating its oral anti-inflammatory and antioxidant lead candidate, AGI-1067, in patients with diabetes. In addition, the Company has other clinical and preclinical anti-inflammatory compounds, including AGI-1096, an oral agent for the prevention of organ transplant rejection. For more information about AtheroGenics, please visit www.atherogenics.com.

www.mffais.com/agix.html

finance.aol.com/company/atherogenics-inc/...tutional-ownership

www.nasdaq.com/asp/quotes_sec.asp...

www.bbbiotech.com/index.php/bbbiotech_de/...on_arteriosklerose

webcastingplayer.corporate-ir.net/player/...eamId=1111999&TIK=

   2 Diabetes or Impaired Fasting Glucose (IFG) in the ARISE Trial." This
   abstract, 2065-PO, by lead author John J. McMurray, M.D., Professor of
   Medical Cardiology, University of Glasgow, and Honorary Consultant
   Cardiologist, Western Infirmary, Glasgow, Scotland, was accepted for
   publication in the ADA Scientific Sessions Abstract Book.
   
--  "AGI-1067, a Novel Antioxidant and Anti-Inflammatory Agent, Improves
   Insulin Sensitivity in a Rat Model of Diet-Induced Obesity," Cynthia L.
   Sundell, Ph.D., Vice President of Pharmacology, AtheroGenics. This poster,
   345-P, will be displayed from Saturday, June 7 through Monday, June 9, 2008
   in the Poster Hall.
   
--  "AGI-1067, a Novel Antioxidant and Anti-Inflammatory Agent, Inhibits
   Activation of JNK, IRS-1 Serine Phosphorylation and Cytokine Production in
   Adipocytes," Xilin Chen, Ph.D., Senior Principal Scientist, AtheroGenics.
   This poster, 1262-P, will be displayed from Saturday, June 7 through
   Monday, June 9, 2008 in the Poster Hall.
   

About AGI-1067

AGI-1067 is a novel oral drug candidate with demonstrated anti-inflammatory and antioxidant properties. AGI-1067 works by selectively inhibiting signaling pathways that are activated in response to oxidative stress and pro-inflammatory stimuli. Oxidative stress and inflammation have been implicated as playing a key role in the pathogenesis of insulin resistance and diabetes.

AtheroGenics recently announced interim results of ANDES, a double-blind, placebo controlled study for the treatment of Type 2 diabetes. ANDES is evaluating two dose levels of AGI-1067 given once daily over six months. The primary efficacy endpoint is change in hemoglobin A1c (A1c) from baseline compared to placebo in patients with Type 2 diabetes. The interim analysis of 806 patients who completed three months in the study showed dose-related, statistically significant reductions in A1c. Final results of the trial are expected in the third quarter 2008.

About AtheroGenics

AtheroGenics is focused on the discovery, development and commercialization of novel drugs for the treatment of chronic inflammatory diseases, including diabetes and coronary heart disease (atherosclerosis). The Company's lead antioxidant and anti-inflammatory drug candidate, AGI-1067, is being studied in a Phase III clinical trial known as ANDES (AGI-1067 as a Novel Anti-Diabetic Agent Evaluation Study), for the treatment of diabetes. In addition, the Company has other clinical and preclinical anti-inflammatory compounds, including AGI-1096, an oral agent for the prevention of organ transplant rejection. For more information about AtheroGenics, please visit www.atherogenics.com.